
\begin{table*}[]
  \centering
   \caption{Population description}
  \label{tab:pop}
\begin{tabular}{llllllllll}
 \hline
%------------------------------------------------------------
&&&&&&&&&\\
 &
\pbox{5cm}{Original publication;\\subsequent analysis} & 
\pbox{5cm}{Location} & 
\pbox{5cm}{Sample\\size} & 
\pbox{5cm}{Males\\(\%)} &
\pbox{5cm}{Mean \\age} &
\pbox{5cm}{Dropout\\rate} & \pbox{5cm}{Treatment\\seeking} & 
\pbox{5cm}{Excluded\\PD} & \pbox{5cm}{Other\\SUD$\ddagger$} \\ %
&&&&&&&&&\\
 \hline
%-------- PANDA ----------------------------------------------------
A
& Sellers 1994 \cite{sellers_clinical_1994} 
& Toronto, Canada %Canada, Toronto 
& 86 
& 100 \%
& 43.6% (9.7)
& 17.4 \% %15/86
& \textbf{yes}
& \textbf{no}$\ast$
& no
\\
%---------------------------------------------
B
& Johnson 2000a \cite{johnson_combining_2000}; \cite{ait-daoud_combining_2001}\cite{ait-daoud_combining_2001-1} 
& San Antonio, USA
& 20
& 75 \%
& 38.0% (1.78)
& 30 \% %1 full, 30% not all visits
& \textbf{yes}
& yes
& no
\\
%---------------------------------------------
C
& Johnson 2000b \cite{johnson_ondansetron_2000}; \cite{johnson_ondansetron_2002}\cite{johnson_ondansetron_2003}\cite{roache_prediction_2008} 
& Houston, USA
& 271% randomized, 271 randomized in \cite{johnson_ondansetron_2000}, 253 in \cite{johnson_ondansetron_2002}
& 70 \%
& 40.6% (0.88)
& 42 \% %1-158/271
& \textbf{yes}
& yes
& no
\\
%---------------------------------------------
D
& Kranzler 2003 \cite{kranzler_effects_2003}
& Farmington, USA 
& 40
& 67.5 \%
& 43.7% (9.76)
& 30 \% %1-28/40
& \textbf{yes}
& yes
& no
\\
%---------------------------------------------
E
& Dawes 2005a \cite{dawes_prospective_2005}; \cite{dawes_reductions_2005}
& San Antonio, USA
& 12
& 58.3 \%
& 18% (2.13)%calc
& 25 \%%3/12
& \textbf{yes}
& \textbf{no}$\ast$
& \textbf{yes}$\dagger$
\\
%---------------------------------------------
F
& Myrick 2008 \cite{myrick_effect_2008}
& Northridge, USA
& 107%17 social drinkers, 90 alcohol dependant
& 72.9 \%
& 25.7
& N.A.
& no
& yes
& \textbf{yes}$\dagger$
\\
%---------------------------------------------
G
& Kenna 2009 \cite{kenna_within-group_2009} 
& Providence, USA
& 20% but15
& 80 \%
& 44.1% (9.5)
& 25 \% %5/20
& no
& yes
& no
\\
%---------------------------------------------
H
& Johnson 2011 \cite{johnson_pharmacogenetic_2011}; \cite{johnson_determination_2013}\cite{seneviratne_serotonin_2012}\cite{hou_subgroup_2015}
& Charlottesville, USA %San Antonio + university of virginia
& 283 %$\dagger$ 41/283 in \cite{seneviratne_serotonin_2012}
& 73.1 \%
& 44.7 
& 33 \% %1-(191/283)
& \textbf{yes}
& yes
& no
\\
%---------------------------------------------
I
& Corrêa Filho 2013 \cite{correa_filho_pilot_2013} 
& São Paulo, Brazil
& 102
& 100 \%
& 42.91
& 50 \% %1-51/102
& Un.
& \textbf{no}$\ast$
& no
\\
%---------------------------------------------
J
& Kenna 2014 \cite{kenna_ondansetron_2014-1}; \cite{kenna_ondansetron_2014}
& Providence, USA
& 77
& 65 \%
& 43.4 %(10.4)
& 29 \% %1-(55/77)
& no
& yes
& no
\\
%---------------------------------------------
K
& Sherwood Brown 2021 \cite{sherwood_brown_randomized_2021}
& Dallas, USA
& 70
& 60 \%
& 44.9
& 34 \% %1-51/102
& Un.
& \textbf{no}
& Un.
\\
 \hline
%------------- PANDA --------------------------------
& Total
&
& \totalrandomized
& \pmales
& \meanage
& \meandropout
& \ptseeking
& \ppsyd
& \psudd
\\
 \hline
\end{tabular}
\caption*{Description of the 11 distinct study population used by the 19 clinical trials. Letters A to K are attributed to each study population in chronological order of first publication for later referral.\\\emph{$\ddagger$:~except nicotine; $\dagger$:~cannabis use allowed; $\ast$:~except clinically significant disorders; c:~except cannabis-use disorder; n:~except nicotine-use disorder; N.A.:~non applicable; PD: psychiatric diagnosis; SD: standard deviation; SUD:~substance-use disorder; Un.:~unknown}}
\end{table*}
%---------------------------------------------------------------------------